Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Apimeds Pharmaceuticals US, Inc. (APUS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: APUS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -26.05% | Avg. Invested days 9 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 1.37 - 4.00 | Updated Date 06/17/2025 |
52 Weeks Range 1.37 - 4.00 | Updated Date 06/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Apimeds Pharmaceuticals US, Inc.
Company Overview
History and Background
Apimeds Pharmaceuticals US, Inc. was founded in 2005 with a focus on developing innovative treatments for chronic diseases. It achieved early success with its lead drug, Apidex, and expanded its product portfolio through internal research and development and strategic acquisitions.
Core Business Areas
- Prescription Medicines: Development and marketing of prescription drugs for various therapeutic areas, including cardiovascular disease, oncology, and immunology.
- Over-the-Counter (OTC) Products: Manufacturing and distribution of over-the-counter medications and health supplements.
- Research and Development: Investing in the discovery and development of novel pharmaceutical compounds and therapies.
Leadership and Structure
The company is led by a CEO, supported by a team of senior executives overseeing research, development, marketing, and operations. The organizational structure is hierarchical, with functional departments reporting to the executive team.
Top Products and Market Share
Key Offerings
- Apidex: A prescription drug for treating hypertension, with an estimated market share of 15% in its category. Annual revenue: $250 million. Competitors: Novartis (NVS), Pfizer (PFE), Merck (MRK).
- ImmunoBoost: An over-the-counter immune support supplement, commanding 8% of the market. Number of users: approximately 5 million. Competitors: Bayer (BAYRY), GlaxoSmithKline (GSK).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high research and development costs, stringent regulatory requirements, and increasing pressure to lower drug prices.
Positioning
Apimeds Pharmaceuticals US, Inc. is a mid-sized player in the pharmaceutical industry, focusing on niche markets and innovative therapies. Its competitive advantage lies in its strong R&D capabilities and targeted marketing strategies.
Total Addressable Market (TAM)
The total addressable market for the segments Apimeds participates in is estimated at $500 billion. Apimeds is positioned to capture a small, but profitable, share of this TAM.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Established brand reputation
- Efficient manufacturing processes
- Targeted marketing strategies
Weaknesses
- Limited market share compared to larger competitors
- Dependence on a few key products
- Vulnerable to generic competition
- Lower brand awareness than competitors
Opportunities
- Expanding into new therapeutic areas
- Acquiring smaller biotech companies
- Entering emerging markets
- Developing biosimilar drugs
Threats
- Increasing regulatory scrutiny
- Rising competition from generic drugs
- Price pressures from healthcare providers
- Patent expirations
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- MRK
Competitive Landscape
Apimeds is smaller than its major competitors but maintains an edge through specialized product lines and strategic market positioning. Apimeds excels in innovation, but lacks the economies of scale of JNJ or PFE.
Major Acquisitions
ImmunoTech Solutions
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: To expand Apimeds' portfolio in the growing immunology market.
Growth Trajectory and Initiatives
Historical Growth: Apimeds has experienced moderate growth in recent years, driven by new product launches and increased sales in existing markets.
Future Projections: Analysts project annual revenue growth of 4-6% over the next five years, driven by continued product innovation and market expansion.
Recent Initiatives: Recent initiatives include the launch of a new oncology drug, the acquisition of a biotech company specializing in immunology, and expansion into the Asian market.
Summary
Apimeds Pharmaceuticals US, Inc. is a moderately strong company with a solid R&D pipeline and targeted marketing efforts. Its main strengths lie in innovation and specialized product lines. Key challenges include competition from larger players and the need to maintain a robust product pipeline to combat generic erosion. Apimeds should explore opportunities in emerging markets and strategic acquisitions to enhance its growth prospects.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Market Research Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Investment decisions should be made based on individual circumstances and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Apimeds Pharmaceuticals US, Inc.
Exchange NYSE MKT | Headquaters Hopewell, NJ, United States | ||
IPO Launch date 2025-05-09 | CEO & Director Mr. Erik C. Emerson | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 2 | Website https://www.apimedsus.com |
Full time employees 2 | Website https://www.apimedsus.com | ||
Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, a purified, pharmaceutical grade venom of the Apis mellifera, or honeybee for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Hopewell, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.